Takeda and Innovent Biologics forge global partnership to advance oncology medicines for solid tumors

Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent

Takeda exits cell therapy research

Takeda will seek an external partner to leverage its cell therapy platform technologies

Takeda appoints Rhonda Pacheco President of US Business Unit

Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO

FDA approves sBLA for Takeda's Vonvendi for Von Willebrand disease

Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD

Abbott India inks non-exclusive patent license agreement with Takeda for Vonoprazan

This license will enable Abbott to enhance access to this novel therapy to more patients across India

Lupin inks licensing agreement with Takeda to commercialize Vonoprazan

Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India

Alkem signs license agreement with Takeda to commercialise Vonoprazan in India

Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)

USAID and Takeda launch dengue prevention campaign

Campaign launched to spread awareness regarding dengue prevention and control

Zydus signs patent licensing agreement with Takeda for 'VaultA’ in India

The pooled prevalence of GERD in the Indian population is 15.6 %

Dr. Reddy's signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan